$INCY insider trading
Over the last 12 months, Incyte insiders reported no purchases and 29 sales totaling $54.1M across SEC Form 4 filings. 100% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $54.1M 29 events
- Events · 12m
- 29 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 100% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | CAGNONI PABLO JPresident, Global Head of R&D · O | ▼ Sale | 10,801 | $125.56 | $1.4M | -5.6% | plan |
| Aug 12, 2026 | CAGNONI PABLO JPresident, Global Head of R&D · O | ▼ Sale | 10,803 | $120.04 | $1.3M | -5.3% | plan |
| Aug 5, 2026 | CAGNONI PABLO JPresident, Global Head of R&D · O | ▼ Sale | 10,640 | $122.69 | $1.3M | -4.9% | plan |
| Aug 5, 2026 | Mayes Patrick AEVP & Chief Scientific Officer · O | ▼ Sale | 2,207 | $123.99 | $274K | -3.5% | plan |
| Aug 3, 2026 | Mayes Patrick AEVP & Chief Scientific Officer · O | ▼ Sale | 47,954 | $119.58 | $5.7M | -43.8% | plan · 12 tranches |
| Jul 31, 2026 | CAGNONI PABLO JPresident, Global Head of R&D · O | ▼ Sale | 15,888 | $119.7 | $1.9M | -6.9% | plan |
| Jul 16, 2026 | Stein Steven HCMO & Head of Late-Stage Dev. · O | ▼ Sale | 1,877 | $114.73 | $215K | -8.2% | plan |
| Jul 16, 2026 | Issa Mohamed KhairieEVP, Head of U.S. Commercial · O | ▼ Sale | 1,093 | $115.01 | $126K | -1.7% | plan |
| Jul 15, 2026 | Stein Steven HCMO & Head of Late-Stage Dev. · O | ▼ Sale | 28,237 | $113.05 | $3.2M | -52% | plan |
| Jun 4, 2026 | Tray ThomasPrincipal Accounting Officer · O | ▼ Sale | 2,639 | $100 | $264K | -11.1% | plan |
| May 26, 2026 | Tray ThomasPrincipal Accounting Officer · O | ▼ Sale | 2,051 | $97.35 | $200K | -8.8% | plan |
| Apr 17, 2026 | CAGNONI PABLO JPresident, Global Head of R&D · O | ▼ Sale | 18,667 | $96.5 | $1.8M | -6.6% | plan |
| Mar 17, 2026 | CAGNONI PABLO JPresident, R&D · O | ▼ Sale | 18,667 | $94.24 | $1.8M | -7.4% | plan |
| Feb 19, 2026 | CAGNONI PABLO JPresident, R&D · O | ▼ Sale | 18,668 | $100.91 | $1.9M | -7.4% | plan |
| Jan 7, 2026 | Issa Mohamed KhairieEVP, Head of US Oncology · O | ▼ Sale | 10,856 | $109.07 | $1.2M | -14.1% | plan |
| Jan 5, 2026 | Stein Steven HEVP & Chief Medical Officer · O | ▼ Sale | 15,634 | $101.7 | $1.6M | -31.4% | plan |
| Dec 19, 2025 | Tray ThomasPrincipal Accounting Officer · O | ▼ Sale | 3,374 | $99.69 | $336K | -12.8% | plan · 2 tranches |
| Dec 17, 2025 | Morrissey Michael JamesEVP, Head of Tech. Operations · O | ▼ Sale | 58,331 | $97.29 | $5.7M | -68% | plan · 3 tranches |
| Dec 11, 2025 | Mayes Patrick AEVP & Chief Scientific Officer · O | ▼ Sale | 5,808 | $95.55 | $555K | -8.8% | plan · 2 tranches |
| Dec 2, 2025 | Stein Steven HEVP & Chief Medical Officer · O | ▼ Sale | 22,664 | $102.56 | $2.3M | -26.4% | plan · 2 tranches |
| Nov 24, 2025 | Tray ThomasPrincipal Accounting Officer · O | ▼ Sale | 769 | $102.78 | $79K | -3.2% | plan · 2 tranches |
| Nov 17, 2025 | Denton Sheila A.EVP & General Counsel · O | ▼ Sale | 278 | $104.36 | $29K | -1% | plan |
| Nov 10, 2025 | Hoppenot HerveD | ▼ Sale | 187,500 | $105.46 | $19.8M | -36.3% | plan |
| Nov 5, 2025 | Stein Steven HEVP & Chief Medical Officer · O | ▼ Sale | 5,233 | $102.2 | $535K | -4.8% | plan |
| Nov 4, 2025 | Denton Sheila A.EVP & General Counsel · O | ▼ Sale | 598 | $101.36 | $61K | -2.2% | plan |
| Nov 3, 2025 | Heeson LeeEVP, Head of Incyte Intl · O | ▼ Sale | 3,074 | $94.02 | $289K | -9.5% | plan |
| Oct 15, 2025 | Denton Sheila A.EVP & General Counsel · O | ▼ Sale | 277 | $85.13 | $24K | -1% | plan |
| Oct 3, 2025 | Denton Sheila A.EVP & General Counsel · O | ▼ Sale | 4,100 | $85.85 | $352K | -13.4% | plan · 2 tranches |
| Sep 16, 2025 | Denton Sheila A.EVP & General Counsel · O | ▼ Sale | 278 | $83.15 | $23K | -0.8% | plan |
| Sep 2, 2025 | Denton Sheila A.EVP & General Counsel · O | ▼ Sale | 598 | $84.97 | $51K | -1.8% | plan |
| Aug 15, 2025 | Denton Sheila A.EVP & General Counsel · O | ▼ Sale | 277 | $86.81 | $24K | -0.8% | plan |
Every $INCY filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Incyte filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $INCY feed.